GÄRUNGSPROZESS

European patent · EP2809343 · In force

Register entry

Publication number
EP2809343
Application number
EP13701484
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 30, 2013
Published
Dec 10, 2014
Granted
Oct 4, 2017
Protection ends at the latest
Jan 29, 2033
Next annual fee due
Jan 31, 2027
IPC classes
A61K 39/00 (2006.01)
Priority
US 201261593541 P 01.02.2012
PCT application
PCT/EP2013/051743 30.01.2013
PCT publication
WO2013/113729 08.08.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  5. Oct 20, 2017

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 20.10.2017

  6. Oct 4, 2017

    Granted

    Published in Swissreg on 04.10.2017

Parties

Holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89, 1330 Rixensart, BE

Agent

Isler & Pedrazzini AG

Postfach 1772, 8027 Zürich

Inventor

DEHOTTAY, Philippe Marc Helene

1330 Rixensart, BE

GOFFIN, Philippe

1330 Rixensart, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.